T cell receptor–Major Histocompatibility Complex antigen recognition pathway (TCR-MHC pathway)

The T cell receptor (TCR)–Major Histocompatibility Complex (MHC) antigen recognition pathway is the fundamental mechanism of the adaptive immune system for identifying non-self antigens (Janeway et al., 2001). This pathway is initiated when a TCR specifically binds to a peptide antigen presented by MHC Class I or Class II molecules on the surface of an opposing cell (NCBI, 2023). This binding event, often stabilized by co-receptors like CD4 or CD8, triggers a complex intracellular signaling cascade involving the CD3 complex and various kinases, ultimately leading to T cell activation, proliferation, and differentiation (StatPearls, 2023). In clinical contexts, this pathway is a major focus for treating autoimmune disorders, preventing organ transplant rejection, and developing cancer immunotherapies (PubMed, 2022). Drugs targeting this pathway range from traditional immunosuppressants like Cyclosporine that block downstream signaling to modern biologics like bispecific T-cell engagers (BiTEs) and TCR-engineered T cells that harness or redirect the pathway's specificity (FDA, 2023).

Other names

TCR-pMHC interactionAntigen presentation pathwayT cell activation signalingMHC-restricted antigen recognition

Modulation of T cell activation through the inhibition of TCR-CD3 signaling, blockade of co-stimulatory molecules, or the use of engineered receptors to redirect T cell specificity toward tumor-associated antigens.